

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 6, 2013
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 6, 2013.

2. Welcome

Thomas Phillips, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Mr. Phillips opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Thomas Phillips, R.Ph.
James Lindsey, MD

Tan Platt, MD

Jony Bollinger, MD

SC DHHS Staff:

Jim Assey, R.Ph.
Janet Giles
Marion Burton, MD
Bryan Amick, PharmD, MBA
Constance Holloway, JD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 7, 2013.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
USC – School of Medicine	Daniel Brown, MD	Pancreatic Enzymes

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Pancreatic Enzymes

Smoking Cessation

Attention Deficit Hyperactivity Disorder (ADHD) Agents

The chart below represents the recommendations from the P & T Committee:

PANCREATIC ENZYMES	
Preferred	Non-Preferred
Creon® Pancrelipase Ultresa® Zenpep®	Pancreaze® Pertzye® Viokace®

SMOKING CESSATION	
Preferred	Non-Preferred
Bupropion SR Chantix® (tab/dose pack) Nicotine Gum Nicotine Lozenge Nicotine Patch	Nicoderm CQ® Nicorette® Gum Nicorette® Lozenge Nicotrol® (Inhalation) Nicotrol NS® (Nasal Spray) Zyban®

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AGENTS	
Preferred	Non-Preferred
Adderall XR® Amphetamine Salt Combo Dexmethylphenidate IR Dextroamphetamine Dextroamphetamine SR Focalin XR®* Intuniv®**	Adderall® Amphetamine Salt Combo XR Concerta® Daytrana® Desoxyn® Dexedrine Dextrostat

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AGENTS <i>(continued)</i>	
Preferred	Non-Preferred
Metadate CD®	Focalin®
Methylphenidate	Methamphetamine
Methylphenidate ER/SR	Methylin® Chew/Solution
Quillivant XR™**	Methylphenidate LA
Ritalin LA®	Procentra® Soln/Dextroamphet
Strattera®	Zenzedi®
Vyvanse™	
*Generic agents considered 1 st line when appropriate	
** Preferred for ages 6 years and older	

5. **Old Business**

None

6. **New Business**

Dr. Amick presented information on weight loss drugs, vaginal progesterones and the Value Based Benefit Design. On weight loss drugs, Dr. Amick indicates these are currently excluded and SC Medicaid will need to obtain CMS' permission to cover. A PDL class will be added for vaginal progesterones. Phase 1 of the Value Based Benefit Design, which will exclude cardiovascular, diabetic, CNS medications and systemic anti-infectives from the current script limits, will be rolled out within 6 weeks or by January 1, 2014 at the latest.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Pancreatic Enzymes

Attention Deficit Hyperactivity Disorder (ADHD) Agents

The P&T Committee tabled the following class for further information:

Smoking Cessation

8. **Closing Comments**

The next meeting will be held on Wednesday, February 5, 2014, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:27 p.m.